Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.
Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines. | 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines. | In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients | 24 weeks |
| Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Subjects who are unwilling or unable to provide informed consent.
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Habib BENNACEUR, MD | AstraZeneca | Study Chair |
| Nawel BOUTEKDJIRET, MD | AstraZeneca | Study Director |
| Yassin BOUHOUITA-GUERMECH, Professor | Cardiology department /Mustapha Bacha Hospital | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| D002318 | Cardiovascular Diseases |
| D006973 | Hypertension |
| D003920 | Diabetes Mellitus |
| D003327 | Coronary Disease |
| D058729 | Peripheral Arterial Disease |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood serum
Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven |
| 24 weeks |
| Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines. | For the following sub-populations: Demographic variables, CV risk factors & Lipid-lowering agent class | 24 weeks |
| The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models | 24 weeks |
| D009750 |
| Nutritional and Metabolic Diseases |
| D014652 | Vascular Diseases |
| D044882 | Glucose Metabolism Disorders |
| D004700 | Endocrine System Diseases |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D016491 | Peripheral Vascular Diseases |